Article

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model

2023-01-04

Abstract excerpt

The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against these Omicron variants in vivo. Our results show t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 56b6ddfc-887f-5946-89b4-c2cc10df350d
DOI: 10.1101/2023.01.04.522629

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster modelDOI 10.1101/2023.01.04.522629Read

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster modelSemantic proximity Read

Sotrovimab Retains Activity Against SARS-CoV-2 Omicron Variant BQ.1.1 in a Nonhuman Primate ModelSemantic proximity Read

Sotrovimab retains activity against SARS-CoV-2 Omicron variant BQ.1.1 in a non-human primate modelSemantic proximity Read

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patientsSemantic proximity Read

Transmission and re-infection of Omicron variant XBB.1.5 in hamstersSemantic proximity Read

Activity of Tixagevimab/Cilgavimab against the Omicron variant of SARS-CoV-2 in a hamster modelSemantic proximity Read

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamstersSemantic proximity Read

Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters.Semantic proximity Read